Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences,” stock code: 688321.SH) announced that its independently developed novel drug Bilessglu® (chiglitazar sodium tablets) has received marketing approval from the Pharmaceutical Administration Bureau (ISAF) of the Macao Special Administrative Region of China. Earlier this year, Epidaza® (chidamide tablets) also received marketing approval in Macao. These approvals mark an important milestone in expanding access to innovative therapies in the Macao market and reflect Chipscreen’s continued commitment to advancing patient-centered innovation.